Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05023018 · ClinicalTrials.gov registry record · Phase 2
NEO100 and High-Grade Meningioma
A Phase 2 study of Residual, Progressive or Recurrent Grade II or III Meningioma, sponsored by Neonc Technologies.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT05023018: Recruiting Phase 2 study of Residual, Progressive or Recurrent Grade II or III Meningioma, sponsored by Neonc Technologies.
NCT05023018 is a Phase 2 study of Residual, Progressive or Recurrent Grade II or III Meningioma that is actively recruiting participants, run by Neonc Technologies. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05023018, a Phase 2 study of Residual, Progressive or Recurrent Grade II or III Meningioma, is actively recruiting participants, sponsored by Neonc Technologies.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle until disease progression, death or patient withdraw from study for any reason, whichever occurs first.
Primary Outcome
Progression free survival
Conditions Studied
Interventions
- DRUG NEO100
Study Locations (3)
California
- University of Southern California - Los Angeles
- Saint John Cancer Institute - Santa Monica
Texas
- Baylor Scott and White - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
What NCT05023018 shows while recruiting
NCT05023018 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Residual, Progressive or Recurrent Grade II or III Meningioma appearing as the primary indexed condition, and to 1 intervention - of which NEO100 is the first listed.
NCT05023018 reports a single indexed study location in California, Texas.
Frequently Asked Questions
What is clinical trial NCT05023018 about?
NCT05023018 is a clinical study titled "NEO100 and High-Grade Meningioma". This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed prog...
What is the current status of trial NCT05023018?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-07-01. Estimated completion is 2027-06-30.
What conditions does trial NCT05023018 study?
This clinical trial studies the following conditions: Residual, Progressive or Recurrent Grade II or III Meningioma.
What interventions are being tested in trial NCT05023018?
The interventions under investigation include: NEO100 (DRUG).
Who is sponsoring clinical trial NCT05023018?
This trial is sponsored by Neonc Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05023018 being conducted?
This trial has 3 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05023018's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI